SHORT REPORT

Novel *SLC25A32* mutation in a patient with a severe neuromuscular phenotype

Debby MEI Hellebrekers^{*1}, Suzanne CEH Salleveld¹, Tom EJ Theunissen^{1,2}, Alexandra TM Hendrickx¹, Ralph W Gottschalk¹, Janneke GJ Hoeijmakers³, Daphna D Habets¹, Jörgen Bierau¹, Kees G Schoonderwoerd⁴ and Hubert JM Smeets^{1,2}

In a 51-year-old patient of consanguineous parents with a severe neuromuscular phenotype of early-onset ataxia, myoclonia, dysarthria, muscle weakness and exercise intolerance, exome sequencing revealed a novel homozygous variant (c.-264_31delinsCTCACAATGCTCA) in the mitochondrial FAD-transporter gene *SLC25A32*. Flavin adenine dinucleotide (FAD) is an essential co-factor for many mitochondrial enzymes and impaired mitochondrial FAD-transport was supported by a reduced oxidative phosphorylation complex II activity in the patient's muscle, decreased ATP production in fibroblasts, and a deficiency of mitochondrial FAD-dependent enzymes. Clinically, the patient showed improvement upon riboflavin treatment, which is a precursor of FAD. Our results confirm the recently reported case of *SLC25A32* as a cause of riboflavin-responsive disease. Our patient showed a more severe clinical phenotype compared with the reported patient, corresponding with the (most likely) complete absence of the *SLC25A32*-encoding MFT (Mitochondrial Folate Transporter) protein.

European Journal of Human Genetics (2017) 25, 886–888; doi:10.1038/ejhg.2017.62; published online 26 April 2017

INTRODUCTION

Mitochondrial disorders are among the most common inherited neuromuscular disorders and are genetically and clinically highly heterogeneous. The limited genotype–phenotype correlations and extreme genetic heterogeneity make selection of a single candidate gene impossible for the majority of patients. Whole-exome sequencing is the best strategy to identify the nuclear genetic defect for these disorders, enabling identification of known disease genes or new candidate genes. Here we identified with exome sequencing a novel homozygous *SLC25A32* null variant, causing complete absence of the protein or production of a dysfunctional protein, and resulting in a patient with a severe neuromuscular phenotype. This is the second patient reported with variants in this gene, the first being a patient with exercise intolerance and biochemical features of multiple acyl-coenzyme A dehydrogenase deficiency.¹

SUBJECTS AND METHODS

Patient

The patient of consanguineous Dutch parents (first cousins) presented at the age of 3 years with muscle weakness after he had suffered from influenza. During childhood, he showed an impaired motor development and exercise intolerance. Subsequently, around the age of 20 years, he developed progressive dysarthria. In the last 10 years, this is accompanied with swallowing difficulties. In addition, he occasionally has myoclonic jerks. He is in a wheelchair (although not continuously) now at age 52. He has 2 brothers and 6 sisters, none of them clinically affected (Supplementary Figure 1a). His blood tests showed an increased lactic acid of 5.7 mmol/l. Stainings of the patient's muscle tissue revealed the presence of many ragged-red fibres, as well as multiple cytochrome oxidase-negative muscle fibres. Biochemical measurement of complex I, complex II+III, complex IV and citrate synthetase activities was performed in muscle tissue as described before.² Activities of the patient's

oxidative phosphorylation (OXPHOS) complexes I, II+III and IV in muscle biopsy revealed a complex II+III activity of approximately 44% of control muscle, indicating an OXPHOS complex II deficiency. Furthermore, measurements of isolated complex II activity in muscle showed a complex II activity of 36% of control muscle. In addition, oxygen consumption rate parameters in patient-derived fibroblasts showed decreased basal respiration levels and ATP production (Supplementary Figure 2).

Whole-exome sequencing

Exome enrichment was performed by the Agilent SureSelectXT exome enrichment kit version 5 (Agilent Technologies, Santa Clara, CA, USA). Sequencing was performed by an Illumina NextSeq500 platform, using a 2 × 150 bp paired-end setting (Illumina, San Diego, CA, USA). Basecalling and demultiplexing was done using bcl2fastq 2.16.0; reads were aligned onto the human reference genome (hg19) by BWA 0.5.9; duplicates were removed using PICARD software suite 1.77 (Broad Institute, Cambridge, MA, USA); variant calling was performed using GATK 2.1-8 (Broad Institute). Annotations were added using an in-house developed annotation pipeline, which uses as resources amongst others Gencode V19, dbSNP144, ExAC v0.2, and CADD v1.3. Results were also compared to an in-house database that contains the occurrences amongst 7788 exomes. Targeted exome analyses of a panel of ~450 nuclear genes was performed, containing known mitochondrial disease genes and functionally or clinically related genes. The data were filtered for homozygous and heterozygous non-synonymous variants, insertions and deletions (both in-frame and frameshift), nonsense variants and splice-variants, with allele frequencies <0.01 in the ExAC database³ and in our in-house database. The impact of missense variants on protein function was estimated using the algorithms integrated in the Alamut software version 2.7 (Rouen, France). The pathogenic variant in *SLC25A32* and the patient's phenotype were submitted to the gene variant database www.LOVD.nl/SLC25A32 (patient ID00092292).

¹Department of Clinical Genetics, Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands; ²Department of Genetics and Cell Biology, School for Oncology and Developmental Biology, Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands; ³Department of Neurology, Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands; ⁴Department of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands

*Correspondence: Dr DMEI Hellebrekers, Department of Clinical Genetics, Maastricht University Medical Centre (MUMC), P. Debeyelaan 25, PO Box 5800, Maastricht 6202 AZ, The Netherlands. Tel: +043 387 1289; Fax: +043 388 4573; E-mail: debby.hellebrekers@mumc.nl

Received 1 November 2016; revised 28 February 2017; accepted 28 March 2017; published online 26 April 2017

Table 1 Metabolic analysis of organic acids (excretion in urine) and acylcarnitine (plasma concentration) in patient as compared with controls

Acylcarnitines	$\mu\text{mol/l}$	Ref range	Conclusion
C4/(Iso)Butyrylcarnitine	3.09	0.04–0.82	Increased
C5/Isovalerylcarnitine + 2-methylbutyrylcarnitine	2.74	0.06–0.50	Increased
C6/Hexanoylcarnitine	0.84	0.02–0.16	Increased
C8/Octanoylcarnitine	2.99	0.02–0.77	Increased
C10/Decanoylcarnitine	2.46	0.03–0.87	Increased
C10:1/Decenoylcarnitine	0.99	0.03–0.46	Increased
C5-DC/Glutarylcarnitine	0.30	0–0.10	Increased
C12/Dodecanoylcarnitine	0.25	0.01–0.25	Increased—within ref range
C14/Tetradecanoylcarnitine	0.06	0–0.11	Within ref range
C14:1/Tetradecenoylcarnitine	0.19	0–0.23	Within ref range
C16/Hexadecanoylcarnitine	0.12	0.03–0.22	Within ref range
C16:1/Hexadecenoylcarnitine	0.04	0–0.09	Within ref range
C18/Octadecanoylcarnitine/Steroylcarnitine	0.11	0.01–0.13	Within ref range
C18:1/Oleylcarnitine	0.12	0.02–0.38	Within ref range
C18:2/Linoleylcarnitine	0.07	0.02–0.23	Within ref range
<i>Organic acids</i>	$\mu\text{mol/mmol creatinine}$	Ref range	Conclusion
Isovalerylglycine	61.4	0–1.2	Increased
3-hydroxy-isovaleric acid	7.6	6.0–49.0	Within ref range
2-methylbutyrylglycine	2.2	0–0.4	Increased
Isobutyrylglycine	3.5	0–1.1	increased
Glutaric acid	1.3	1.0–4.0	Within ref range
2-hydroxy-glutaric acid	15.5	4.0–16.0	Within ref range
Ethylmalonic acid	68.7	2.0–10.0	Increased
Hexanoylglycine	1.3	0–0.3	Increased
Suberylglycine	0.2	0–0.1	Increased
Adipic acid	2.6	1.0–7.0	Within ref range
Suberic acid	0.9	1.0–6.0	Within ref range
Sebacic acid	0.6	0	Increased
3-hydroxy-sebacic acid	0.5	0–4.0	Within ref range

Metabolic investigations were performed before riboflavin supplementation.

RESULTS

Whole-exome sequencing was performed to identify the underlying genetic defect in the patient. Since the patient was suspected of having a mitochondrial disorder, targeted exome analyses of known mitochondrial disease genes, as well as functionally or clinically related genes, was performed. After filtering variants on allele frequency and predicted impact on protein function, only *SLC25A32* contained two mutated alleles. The patient was homozygous for the *SLC25A32* c.-264_31delinsCTCACAAATGCTCA variant (NM_030780.4), a novel variant that is not present in any of the SNP-databases and not reported before in patients. The presence of the variant was confirmed by Sanger sequencing in the index patient, whereas the variant was not detected in an unaffected brother (Supplementary Figure 1a). Other siblings, as well as the patient's parents, were not available for testing.

The c.-264_31delinsCTCACAAATGCTCA variant deletes the methionine (AUG) translation start codon (Supplementary Figure 1b), resulting in complete absence of the MFT protein or, alternatively, production of a dysfunctional protein due to the use of a downstream translation start codon. The second AUG-codon in the *SLC25A32* gene is located in exon 4, however, this is not in the context of a Kozak consensus sequence required for translation initiation.⁴ It is therefore most likely that the homozygous variant in our patient causes complete loss of the MFT protein.

MFT is a mitochondrial transporter of flavin adenine dinucleotide (FAD), a co-factor required for many mitochondrial enzymes. A causal role for the *SLC25A32* variant in the patient's clinical and

biochemical phenotype was therefore confirmed by the reduced activity of OXPHOS complex II, containing FAD-dependent succinate dehydrogenase (SDH), in the patient's muscle. Further support for the link between the *SLC25A32* gene and the patient's phenotype was obtained from metabolic investigations (Table 1). Analysis of urinary organic acids revealed strongly increased excretion of isovalerylglycine, isobutyrylglycine and ethylmalonic acid, and acylcarnitine profiling in plasma showed increased levels of (iso)butyryl-, isovaleryl-, hexanoyl-, octanoyl-, decenoyl-, decanoyl- and glutaryl- carnitine esters. These metabolic results indicate decreased activities of multiple acyl-coenzyme A dehydrogenases in the patient, corresponding with a dysfunctional FAD-transport.

After identification of the damaging variant in the *SLC25A32* gene, encoding the mitochondrial FAD-transporter (MFT), as the causal genetic defect in the patient, oral supplementation with riboflavin at a dose of 10 mg three times a day was started. This showed improvement in the patient's clinical condition: Before starting the riboflavin treatment, he was able to walk a maximum distance of 100 m. One and a half month after starting riboflavin supplementation, the patient could walk at least 500 m. His endurance was increased, without a change in muscle strength.

DISCUSSION

Using whole-exome sequencing, we identified a novel homozygous variant in the *SLC25A32* FAD-transporter gene causing a severe neuromuscular phenotype in a consanguineous Dutch family. The *SLC25A32* c.-264_31delinsCTCACAAATGCTCA variant completely

abolishes the translation start codon and it is therefore highly likely that the protein is either completely absent or dysfunctional, when an alternative start codon would be used. On the basis of this, we concluded that no functional MFT protein could be formed, and therefore we did not perform follow-up experiments. Because the patient's parents were not available for testing, the 'apparently' homozygous *SLC25A32* variant can theoretically be hemizygous, due to a large deletion of one allele, which can not be detected by both sequencing methods used (exome sequencing and Sanger sequencing). Nevertheless, the consanguinity of the parents (first cousins) and the large homozygous region (LOH region) in which the variant is located, as shown in the exome data (data not shown), make homozygosity of the *SLC25A32* variant in the patient highly likely.

Only one other, recently reported patient has been described with *SLC25A32* variants.¹ Remarkably, in comparison with the reported patient with late-onset exercise intolerance, our patient suffers from more severe, heterogeneous symptoms, involving early-onset ataxia, myoclonia, dysarthria, muscle weakness and exercise intolerance. The severe neuromuscular phenotype of our patient is probably explained by the type of variant resulting (very likely) in complete absence of the MFT protein, while the reported *SLC25A32*-patient with a milder phenotype is compound heterozygous for a nonsense and a missense variant.

MFT is a member of the large family of SLC25 solute carrier.⁵ Embedded in the inner mitochondrial membrane, MFT transports flavin adenine dinucleotide (FAD) from the cytosol into the mitochondria.⁶ The presence of mitochondrial FAD is necessary for many mitochondrial enzymes, including succinate dehydrogenase (SDH) and multiple acyl-coenzyme A dehydrogenases. Therefore, reduced mitochondrial FAD levels results in, amongst others, decreased mitochondrial β -oxidation and oxidative phosphorylation.

Supplementation with the FAD precursor riboflavin, or vitamin B2, raises the intra-mitochondrial FAD concentration, which might compensate for the decreased FAD binding of enzymes.⁷ This is reflected by the clinical improvement of our patient upon riboflavin treatment.

In conclusion, we report the second patient with damaging variants in the *SLC25A32* gene as a novel cause of riboflavin-responsive neuromuscular disease. Our data show that *SLC25A32* variants can manifest clinically quite divers. *SLC25A32* should be added to the list of candidate genes for patients with neuromuscular symptoms suspected of having a mitochondrial disorder, especially in case of a biochemical phenotype of FAD deficiency.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

- 1 Schiff M, Veauville-Merli A, Su CH *et al*: *SLC25A32* mutations and riboflavin-responsive exercise intolerance. *N Engl J Med* 2016; **374**: 795–797.
- 2 Sgobbo P, Pacelli C, Grattagliano I, Villani G, Cocco T: Carvedilol inhibits mitochondrial complex I and induces resistance to H2O2-mediated oxidative insult in H9C2 myocardial cells. *Biochim Biophys Acta* 2007; **1767**: 222–232.
- 3 Lek M, Karczewski KJ, Minikel EV *et al*: Analysis of protein-coding genetic variation in 60 706 humans. *Nature* 2016; **536**: 285–291.
- 4 Kozak M: Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. *Cell* 1986; **44**: 283–292.
- 5 Palmieri F: The mitochondrial transporter family SLC25: identification, properties and physiopathology. *Mol Aspects Med* 2013; **34**: 465–484.
- 6 Spaan AN, Ijlst L, van Roermund CW *et al*: Identification of the human mitochondrial FAD transporter and its potential role in multiple acyl-CoA dehydrogenase deficiency. *Mol Genet Metab* 2005; **86**: 441–447.
- 7 Henriques BJ, Lucas TG, Gomes CM *et al*: Therapeutic approaches using riboflavin in mitochondrial energy metabolism disorders. *Curr Drug Targets* 2016; **17**: 1527–1534.

Supplementary Information accompanies this paper on European Journal of Human Genetics website (<http://www.nature.com/ejhg>)